Research Areas
In this section, by far, most Axon Ligands™ are categorized as research tools that find their application in cell signaling and oncology. Targeting a multitude of specific enzymes and receptors, they either stimulate or block particular cellular signaling pathways that are implicated in various kinds of cancer. Naturally, all products in this section can also be found by their specific biological targets as listed in the sections of enzymes, receptors, transcription factors, proteins and/or signaling pathways. Besides the comprehensive set of compounds that targe cell signaling and oncology, selections of Axon Ligands™ have also been made for other research area's such as cardiovascular diseases, angiogenisis, epigenetics, stem cell research, among many others.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1831 | A 66 | PI3K inhibitor (p110-α specific) | €95.00 | |
| 2857 | Acalisib | PI3K inhibitor (p110 δ specific) | €120.00 | |
| 2540 | Akt Inhibitor VIII | Inhibitor of Akt1 and 2 with significant off-side effects (CaMKIα and AhR) | €95.00 | |
| 2925 | Alpelisib | PI3K inhibitor (p110-α specific) | €90.00 | |
| 3827 | AMG-511 | Orally bioavailable, highly potent and selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor | Inquire | |
| 1424 | AS 252424 | PI3K inhibitor (p110-γ specific) | €85.00 | |
| 1436 | AS 252424 bispotassium salt | PI3K inhibitor (p110-γ specific) | €95.00 | |
| 2748 | Autophinib | PIK3C3/Vps34 inhibitor | €120.00 | |
| 3996 | AZD2014 | Orally bioavailable dual mTORC1/mTORC2 inhibitor | Inquire | |
| 3808 | AZD3458 | Orally bioavailable potent and selective PI3Kγ inhibitor | Inquire | |
| 1859 | AZD5363 dihydrochloride | Inhibitor of protein kinase B (Akt) | €90.00 | |
| 2926 | AZD6482 | PI3K inhibitor (p110 β specific) | €120.00 | |
| 1561 | AZD8055 | mTOR inhibitor | €80.00 | |
| 3690 | AZD8186 | PI3Kβ/δ isoform-selective inhibitor | Inquire | |
| 3055 | B591 | Potent, specific class I PI3K inhibitor | €125.00 | |
| 1282 | BAG 956 | PI3K and PDPK1 inhibitor | €95.00 | |
| 3778 | BAY-091 | First potent and highly selective PIP4K2A inhibitor | €130.00 | |
| 3598 | BAY-091 hydrochloride | First potent and highly selective PIP4K2A inhibitor | €130.00 | |
| 3942 | BAY-1082439 | PI3Kα/β-balanced inhibitor | Inquire | |
| 1281 | BEZ 235 | PI3K and mTOR tyrosine kinase inhibitor | €50.00 | |
| 2801 | BQR695 | PI4K inhibitor | €105.00 | |
| 1390 | BX 795 | PDPK1, TBK1 and IKK inhibitor | €60.00 | |
| 3350 | BX 795 hydrochloride | PDPK1, TBK1 and IKK inhibitor | €80.00 | |
| 1130 | BX 912 | PDPK1 inhibitor | €80.00 | |
| 2170 | CAL 101 | PI3K inhibitor (p110 δ specific) | €95.00 | |
| 4038 | CEP-37440 hydrochloride | Potent, selective and orally active inhibitor of ALK anf FAK | Inquire | |
| 2039 | CZC 24832 | PI3K inhibitor (p110-γ specific) | €95.00 | |
| 1719 | D 106669 | Potent and selective PI3K inhibitor | €85.00 | |
| 1239 | Deguelin | Akt inhibitor | €95.00 | |
| 2630 | eCF309 | Highly selective and potent inhibitor of mTOR signalling | €85.00 | |